Chengdu Jinrui Jiye Biotechnology

Chengdu Jinrui Jiye Biotechnology is a biopharmaceutical company based in China that focuses on the research, development, and large-scale production of recombinant protein therapeutics. The company's primary focus is its recombinant human serum albumin (rHSA) program, which utilizes a yeast-based expression system to provide a safe and scalable alternative to human plasma-derived albumin. Jinrui Jiye's technology aims to solve the chronic shortage of blood products and eliminate the risk of blood-borne pathogen transmission. The company has established a comprehensive GMP-compliant manufacturing infrastructure in Chengdu to support its clinical and commercial goals. Its pipeline also includes other recombinant proteins and potential antibody candidates for various clinical indications. The company is recognized as a key player in China's national efforts to develop blood product substitutes.